EGFR Targeted PLGA Nanoparticles Using Gemcitabine for Treatment of Pancreatic Cancer
EGFR Targeted PLGA Nanoparticles Using Gemcitabine for Treatment of Pancreatic Cancer
复制标题
DOI：
10.1166/jbn.2011.1238
复制
发表时间：
2011-02-01
影响因子：
2.9
通讯作者：
Gupta, Swati
中科院分区：
文献类型：
--
作者：
Aggarwal, Sahil;Yadav, Sachin;Gupta, Swati
本研究的目的是制备和表征抗EGFR单克隆抗体（mAb）结合的吉西他滨负载PLGA纳米粒，用于其选择性递送到胰腺细胞和体外评价系统。据观察，抗体与戊二醛活化的纳米颗粒的直接共价偶联是实现基于聚合物纳米颗粒的细胞类型特异性药物载体系统的适当方法，所述聚合物纳米颗粒具有应用于EGFR阳性癌症中的靶向化疗的潜力。
The present study aimed to prepare and characterize anti EGFR monoclonal antibody (mab) conjugated Gemcitabine loaded PLGA nanoparticles for their selective delivery to pancreatic cells and evaluation of the systems in vitro. It was observed that direct covalent coupling of antibodies to glutaraldehyde activated nanoparticles is an appropriate method to achieve cell-type specific drug carrier systems based on polymeric nanoparticles that have potential to be applied for targeted chemotherapy in EGFR positive cancer.